Efficacy of the VEGF-C/D Inhibitor OPT-302 in Combination With the VEGF-A Inhibitor Ranibizumab in Patients With Neovascular AMD
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Ophthalmology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A Randomized Controlled Trial of OPT-302, a VEGF-C/D Inhibitor for Neovascular Age-Related Macular Degeneration
Ophthalmology 2023 Jun 01;130(6)588-597, TL Jackson, J Slakter, M Buyse, K Wang, PU Dugel, CC Wykoff, DS Boyer, M Gerometta, ME Baldwin, CF PriceFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.